Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05657860 · ClinicalTrials.gov registry record · Phase 4
Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
A Phase 4 study, sponsored by Maimonides Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT05657860 is a Phase 4 study that has completed, run by Maimonides Medical Center. The registered enrollment target is 15 participants.
The verdict
NCT05657860, a Phase 4 study, has completed, sponsored by Maimonides Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a placebo-controlled clinical trial to assess whether Guanfacine Extended Release (GXR) reduces aggression and self injurious behavior in individuals with Prader Willi Syndrome (PWS). In addition, the study will establish the safety of GXR with a specific focus on metabolic effects.
Interventions
- OTHER Placebo
- DRUG Guanfacine Extended Release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-12-17 |
| Est. Completion | 2023-12-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05657860
The ClinicalTrials.gov registry entry for NCT05657860 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Maimonides Medical Center, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05657860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05657860 about?
NCT05657860 is a clinical study titled "Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome". This is a placebo-controlled clinical trial to assess whether Guanfacine Extended Release (GXR) reduces aggression and self injurious behavior in individuals with Prader Willi Syndrome (PWS). In addition, the study will establish the safety of GXR with a specific focus on metabolic effects.
What is the current status of trial NCT05657860?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2020-12-17. Estimated completion is 2023-12-16.
What interventions are being tested in trial NCT05657860?
The interventions under investigation include: Placebo (OTHER), Guanfacine Extended Release (DRUG).
Who is sponsoring clinical trial NCT05657860?
This trial is sponsored by Maimonides Medical Center, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.